RARE DISEASE
Infant botulism
Infant botulism
Infant botulism
Synonyms: Infant intestinal botulism, Infant intestinal toxemia botulism, Infant intestinal toxin-mediated botulism, Infantile botulism
Synonyms: Infant intestinal botulism, Infant intestinal toxemia botulism, Infant intestinal toxin-mediated botulism, Infantile botulism
Synonyms: Infant intestinal botulism, Infant intestinal toxemia botulism, Infant intestinal toxin-mediated botulism, Infantile botulism
Drug discovery
1
drug
With orphan designation
Overview
Infant botulism is a neuroparalytic disorder caused by intestinal colonization with Clostridium botulinum spores, which produce neurotoxins (A/B most common). It presents with constipation, hypotonia, cranial nerve deficits, and progressive flaccid paralysis, often requiring respiratory support. Early diagnosis (clinical suspicion ± stool toxin testing) and immediate treatment with botulism immune globulin (BabyBIG®) significantly reduce morbidity [1][6][10][16].
Therapies
BabyBIG® (antibody antitoxin): Reduces hospitalization from ~5.7 to ~2.3 weeks when administered early [3][10][16].
Supportive care: Ventilatory support (20–60% require intubation), enteral/parenteral nutrition, and monitoring for autonomic dysfunction [3][6][9].
Avoid aminoglycosides and clostridiocidal antibiotics, which may exacerbate paralysis [3][10].
Categories: rare infectious diseases, rare neurological diseases, rare ophthalmic disorders
Research Papers
717 drug discovery papers about Infant botulism, with 1 first-in-class and 4 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
717 drug discovery papers about Infant botulism, with 1 first-in-class and 4 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-06-24 | Acquisition of Stickland-metabolizing bacteria during infancy prevents Clostridium botulinum infection
Summary The mechanisms by which maturation of the infant gut microbiota promotes resistance to pathogen colonization remain poorly understood. Infant botulism, a potentially fatal disease caused by intestinal colonization by Clostridium botulinum , provides a striking example of age-dependent susceptibility to infection 1 . Although the gut microbiota has long been implicated in protection against C. botulinum 2–6 , the responsible bacterial species and underlying mechanisms have yet to be elucidated. Here, we show that acquisition of Stickland-metabolizing Clostridia during infant gut microbiota maturation confers resistance to C. botulinum colonization through competition for shared amino-acid-dependent nutritional niches. In human fecal microbiota-transplanted mice, longitudinally collected infant microbiotas exhibited a clear transition from susceptibility to resistance. Intestinal metabolomic analysis identified 5-aminovalerate as a hallmark metabolite of the resistant microbiota, implicating Stickland metabolism, an amino acid metabolic pathway also utilized by C. botulinum . Guided by this finding, metagenomic analysis revealed enrichment of Stickland-metabolizing Clostridia in resistant microbiotas, including Clostridioides difficile , a bacterium frequently carried by healthy infants. Intestinal metabolic signatures of C. botulinum and infant-derived Stickland-metabolizing Clostridia suggested competition for shared amino-acid-dependent nutritional niches. Consistent with this model, C. difficile suppressed C. botulinum expansion through nutrient competition. Together, these findings identify nutritional niche competition as a mechanism by which microbiota maturation promotes resistance to C. botulinum colonization. This work demonstrates how acquisition of specific microbial metabolic functions during early life can shift the gut microbiota from a susceptible to a resistant state.
2026-06-17 | When BAT Precedes BIG-IV in Infant Botulism: The Need for Structured Antitoxin Decision-Pathway Reporting in Case Reports.
In infant botulism, use of equine-derived botulinum antitoxin before BIG-IV may be clinically justified when the infant-specific product is delayed. Future case reports should document the treatment decision pathway, antitoxin timing, risk-benefit justification, guardian counseling, adverse-event monitoring, and relapse-prevention rationale to make such emergency decisions reproducible.
2026-06-02 | Botulinum neurotoxin: from molecular pathogenesis to emerging countermeasures.
Botulism is a severe neuroparalytic syndrome caused by botulinum neurotoxins (BoNTs)-among the most potent biological agents-with an estimated human lethal dose (LD50) of approximately 1 ng/kg. By cleaving soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins at cholinergic nerve terminals, BoNTs block acetylcholine release, producing potentially fatal flaccid paralysis. Despite advances in supportive care, current therapeutic options remain limited to antitoxin administration, which is effective only against circulating toxin and cannot neutralize intracellular BoNT. Consequently, patients often require prolonged mechanical ventilation and rehabilitation. To address these limitations, this review provides a comprehensive overview of botulism, spanning historical recognition, structural and mechanistic insights into BoNT activity, clinical manifestations, and current treatment strategies, while highlighting therapeutic gaps. Particular emphasis is placed on emerging preclinical interventions, including small-molecule inhibitors, antibody-based therapeutics, intracellular clearance strategies, and gene- and RNA-based modalities, reflecting rapid progress in structural biology and pharmacology. Collectively, these advances highlight both the promise and the remaining translational challenges of developing next-generation countermeasures, with implications for clinical management and biodefense preparedness.
2026-05-20 | Development of novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid derivatives for inhibiting the catalytic activity of botulinum neurotoxins type B and F: in silico, in vitro & in vivo evaluation.
Botulinum neurotoxins (BoNTs) are the most pernicious toxin and category 'A' bioterrorism agent, responsible for 'botulism', a rare but fatal disease. Toxins are divided into seven toxinotypes from A-G, where A, B, E, and F are accountable for human botulism. The available treatment strategies are inadequate and ineffective for post-neuronal intoxication. We report novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid derivatives targetingthe catalytic site of VAMP-acting serotypes (BoNT/B and F). Inhibitory potential of the synthesized compounds was studied using a framework of in silico and experimental approaches. Inhibitory activity and binding affinity were evaluated using substrate-based cleavage and SPR assays. Compound efficacy was tested in mice through pre-mixed, prophylactic, and therapeutic strategies. Molecular dynamics simulations analyzed binding interactions, structural fluctuations, and complex stability. Endopeptidase assay revealed that the selected compounds displayed ≥ 80% inhibition of BoNT/B and F catalytic activity, with IC50 values ranging from 17.58 to 34.05 µM. SPR analysis displayed binding affinity of these molecules ranging from 8.13E-06 to 7.69E-04 for both the proteins. In the mouse bioassay, the selected molecules displayed complete protection and extension in survival of up to 20-fold. MD simulation study supported the experimental finding, revealing key interactions with HExxH and other active site residues forming stable conformation throughout the simulation time. Among them, compounds A15 and A36 were predicted to be more effective inhibitors of BoNT/B and F serotypes, respectively. These findings could lay a promising way for the development of novel therapeutics by reducing disease severity, enhancing survivability, and recovery where no post-exposure therapy presently available.
2026-03-06 | Investigating the dual nature of Clostridium botulinum: pathogenic mechanisms and therapeutic potentials.
Clostridium botulinum (C. botulinum) is known for producing one of the strongest neurotoxins, namely botulinum neurotoxin (BoNT). This toxin is responsible for causing botulism, which is considered a severe neurological disease. This comprehensive narrative review highlights the dual nature of C. botulinum as both a serious health threat and a groundbreaking therapeutic agent. Methods: A comprehensive literature search was conducted in Google Scholar, PubMed/Medline, and Scopus (1971-2025, 2020-2025 literary focus) using keywords related to botulism pathogenesis, clinical features, and therapeutic approaches. Key findings indicate that, despite advancements in botulism management and reduced mortality due to heptavalent botulinum antitoxin (HBAT) and botulism immune globulin intravenous (BIG-IV) antitoxins, diagnostic challenges and bacterial spore resistance, particularly in group I, remain persistent. On the other hand, the discovery of serotype BoNT/X with lower toxicity in vertebrates and unique capabilities has opened new horizons in the design of safer treatments. C. botulinum represents a remarkable paradox in biology, an organism capable of producing one of the deadliest toxins known, yet simultaneously a cornerstone in modern therapeutic innovation. In fact, this toxin's dual nature is based on its selective targeting of BoNTs. In this regard, the systemic entry and distribution of this poison in the body - or, in other words, intoxication with it - poses a life-threatening aspect. On the other hand, the use of this bacterium's toxin for therapeutic and medicinal purposes is progressing due to its topical and controlled administration and entry into the body make it a targeted and effective therapeutic tool in the field of medicine. A better and more precise understanding of the mechanisms of action and, if necessary, future structural and engineered modifications in the toxin could lead to the emergence of a new generation of BoNTs that hold promise for the development of esthetic and therapeutic applications in medicine.
2026-06-24 | Acquisition of Stickland-metabolizing bacteria during infancy prevents Clostridium botulinum infection
Summary The mechanisms by which maturation of the infant gut microbiota promotes resistance to pathogen colonization remain poorly understood. Infant botulism, a potentially fatal disease caused by intestinal colonization by Clostridium botulinum , provides a striking example of age-dependent susceptibility to infection 1 . Although the gut microbiota has long been implicated in protection against C. botulinum 2–6 , the responsible bacterial species and underlying mechanisms have yet to be elucidated. Here, we show that acquisition of Stickland-metabolizing Clostridia during infant gut microbiota maturation confers resistance to C. botulinum colonization through competition for shared amino-acid-dependent nutritional niches. In human fecal microbiota-transplanted mice, longitudinally collected infant microbiotas exhibited a clear transition from susceptibility to resistance. Intestinal metabolomic analysis identified 5-aminovalerate as a hallmark metabolite of the resistant microbiota, implicating Stickland metabolism, an amino acid metabolic pathway also utilized by C. botulinum . Guided by this finding, metagenomic analysis revealed enrichment of Stickland-metabolizing Clostridia in resistant microbiotas, including Clostridioides difficile , a bacterium frequently carried by healthy infants. Intestinal metabolic signatures of C. botulinum and infant-derived Stickland-metabolizing Clostridia suggested competition for shared amino-acid-dependent nutritional niches. Consistent with this model, C. difficile suppressed C. botulinum expansion through nutrient competition. Together, these findings identify nutritional niche competition as a mechanism by which microbiota maturation promotes resistance to C. botulinum colonization. This work demonstrates how acquisition of specific microbial metabolic functions during early life can shift the gut microbiota from a susceptible to a resistant state.
2026-06-17 | When BAT Precedes BIG-IV in Infant Botulism: The Need for Structured Antitoxin Decision-Pathway Reporting in Case Reports.
In infant botulism, use of equine-derived botulinum antitoxin before BIG-IV may be clinically justified when the infant-specific product is delayed. Future case reports should document the treatment decision pathway, antitoxin timing, risk-benefit justification, guardian counseling, adverse-event monitoring, and relapse-prevention rationale to make such emergency decisions reproducible.
2026-06-02 | Botulinum neurotoxin: from molecular pathogenesis to emerging countermeasures.
Botulism is a severe neuroparalytic syndrome caused by botulinum neurotoxins (BoNTs)-among the most potent biological agents-with an estimated human lethal dose (LD50) of approximately 1 ng/kg. By cleaving soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins at cholinergic nerve terminals, BoNTs block acetylcholine release, producing potentially fatal flaccid paralysis. Despite advances in supportive care, current therapeutic options remain limited to antitoxin administration, which is effective only against circulating toxin and cannot neutralize intracellular BoNT. Consequently, patients often require prolonged mechanical ventilation and rehabilitation. To address these limitations, this review provides a comprehensive overview of botulism, spanning historical recognition, structural and mechanistic insights into BoNT activity, clinical manifestations, and current treatment strategies, while highlighting therapeutic gaps. Particular emphasis is placed on emerging preclinical interventions, including small-molecule inhibitors, antibody-based therapeutics, intracellular clearance strategies, and gene- and RNA-based modalities, reflecting rapid progress in structural biology and pharmacology. Collectively, these advances highlight both the promise and the remaining translational challenges of developing next-generation countermeasures, with implications for clinical management and biodefense preparedness.
2026-05-20 | Development of novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid derivatives for inhibiting the catalytic activity of botulinum neurotoxins type B and F: in silico, in vitro & in vivo evaluation.
Botulinum neurotoxins (BoNTs) are the most pernicious toxin and category 'A' bioterrorism agent, responsible for 'botulism', a rare but fatal disease. Toxins are divided into seven toxinotypes from A-G, where A, B, E, and F are accountable for human botulism. The available treatment strategies are inadequate and ineffective for post-neuronal intoxication. We report novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid derivatives targetingthe catalytic site of VAMP-acting serotypes (BoNT/B and F). Inhibitory potential of the synthesized compounds was studied using a framework of in silico and experimental approaches. Inhibitory activity and binding affinity were evaluated using substrate-based cleavage and SPR assays. Compound efficacy was tested in mice through pre-mixed, prophylactic, and therapeutic strategies. Molecular dynamics simulations analyzed binding interactions, structural fluctuations, and complex stability. Endopeptidase assay revealed that the selected compounds displayed ≥ 80% inhibition of BoNT/B and F catalytic activity, with IC50 values ranging from 17.58 to 34.05 µM. SPR analysis displayed binding affinity of these molecules ranging from 8.13E-06 to 7.69E-04 for both the proteins. In the mouse bioassay, the selected molecules displayed complete protection and extension in survival of up to 20-fold. MD simulation study supported the experimental finding, revealing key interactions with HExxH and other active site residues forming stable conformation throughout the simulation time. Among them, compounds A15 and A36 were predicted to be more effective inhibitors of BoNT/B and F serotypes, respectively. These findings could lay a promising way for the development of novel therapeutics by reducing disease severity, enhancing survivability, and recovery where no post-exposure therapy presently available.
2026-03-06 | Investigating the dual nature of Clostridium botulinum: pathogenic mechanisms and therapeutic potentials.
Clostridium botulinum (C. botulinum) is known for producing one of the strongest neurotoxins, namely botulinum neurotoxin (BoNT). This toxin is responsible for causing botulism, which is considered a severe neurological disease. This comprehensive narrative review highlights the dual nature of C. botulinum as both a serious health threat and a groundbreaking therapeutic agent. Methods: A comprehensive literature search was conducted in Google Scholar, PubMed/Medline, and Scopus (1971-2025, 2020-2025 literary focus) using keywords related to botulism pathogenesis, clinical features, and therapeutic approaches. Key findings indicate that, despite advancements in botulism management and reduced mortality due to heptavalent botulinum antitoxin (HBAT) and botulism immune globulin intravenous (BIG-IV) antitoxins, diagnostic challenges and bacterial spore resistance, particularly in group I, remain persistent. On the other hand, the discovery of serotype BoNT/X with lower toxicity in vertebrates and unique capabilities has opened new horizons in the design of safer treatments. C. botulinum represents a remarkable paradox in biology, an organism capable of producing one of the deadliest toxins known, yet simultaneously a cornerstone in modern therapeutic innovation. In fact, this toxin's dual nature is based on its selective targeting of BoNTs. In this regard, the systemic entry and distribution of this poison in the body - or, in other words, intoxication with it - poses a life-threatening aspect. On the other hand, the use of this bacterium's toxin for therapeutic and medicinal purposes is progressing due to its topical and controlled administration and entry into the body make it a targeted and effective therapeutic tool in the field of medicine. A better and more precise understanding of the mechanisms of action and, if necessary, future structural and engineered modifications in the toxin could lead to the emergence of a new generation of BoNTs that hold promise for the development of esthetic and therapeutic applications in medicine.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Infant botulism, including 1 approved therapy.
1 orphan drug designation for Infant botulism, including 1 approved therapy.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Botulism immune globulin [BabyBIG] | antibodies | FDA | 1989-01-31 | 2003-10-23 | California Department of Public Health |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.